Director of Chemistry Research & Development
Dr. Amy Han is an accomplished contributor to the Drug Discovery and Development industry. Dr. Han, a 20-year veteran, is currently directing ADC effort at Regeneron Pharmaceuticals. Prior to Regeneron, she held numerous senior scientific positions at leading pharmaceutical companies like Dupont Merck, Dupont Pharmaceutical, BMS, Incyte, and Progenics. She has led and managed multiple drug discovery and development programs, covering multi-therapeutic areas from initiation through to clinical trial stages. During her tenure at Regeneron, Dr. Han also discovered novel cytotoxic payloads for cancer and non-cytotoxic payloads for beyond cancer, as well as novel linker platform for large/small molecular conjugations and stability in vitro and in vivo. Dr. Han has led and made critical contributions on ADC programs; she also has authored 60+ patents, and have presented at numerous domestic and international conferences. In addition to her technical accomplishments, she has also managed teams, both internal as well as remote teams in domestic and internationally based Contract Research Organizations (CROs).
Dian is a Scientist in Drug Metabolism and Pharmacokinetics (DMPK) at Genentech. Her primary interest is focused on small molecule drug metabolism in discovery stage. In this role, her responsibilities include: 1) developing new generation assays for metabolite identification (Met ID) to improve the throughput and tackle challenges associated with drug metabolite ID; 2) exploring deep understanding of metabolite formation and biological impact, and establish structure−activity relationship (SAR) for drug metabolites. Prior to Feb 2017, Dian was a scientist in the BioAnalytical Sciences-Assay Development & Technology Department (BAS-ADT) at Genentech. In this role, her major interest lied in biotransformation and bioanalysis of antibody-drug conjugates (ADCs) using immunoaffinity capture, high-pressure liquid chromatography (HPLC) and mass spectrometry (MS) strategies. Before joining Genentech in 2012, Dian held a postdoctoral position at the NIH Proteomics Research Resource for Integrative Biology in Pacific Northwest National Laboratory. She earned her Ph. D. in Chemistry in 2010 from Washington University in St. Louis under the direction of Michael L. Gross and John-Stephen A. Taylor. Dian has published her recent research on ADC biotransformations in Analytical Chemistry and Bioconjugate Chemistry. Her earlier research was published in multiple journals including J. Am. Chem. Soc. (JACS) and Proc. Natl. Acad. Sci. (PNAS). She has served as a co-chair for conference workshops and peer reviewer for several scientific journals.
Chief Executive Officer
Dr. Gang Qin has more than 16 years of R&D and managing experiences in biomedical research. He obtained his PhD degree at the European Neuroscience Institute, then he joined Max-Planck Institute of Biochemistry focusing on mechanistic characterization of protein degradation regulated cell proliferation. Thereafter, he moved back China and led one team at National Laboratory for Industrial Enzyme Engineering, CAS. At 2013 Dr. Qin founded GeneQuantum Healthcare (Suzhou ) Co. Ltd, currently he is the president. Dr. Qin has published series of high citation paper, he is also major inventor of multiple PCT patents. GeneQuantum’s innovative Ligase Dependent Conjugation (LDC) technology, combined with IP protected Automatic On-line Monitoring Conjugation System and Linker Screening& Optimization Facility, provide a holistic solution for the R&D of next generation ADCs. GeneQuantum are focusing on developing series of next generation anti-tumor ADCs with best-in-class or first-in-class potential fulfilling the unmet clinical need.
Vice President Scientific Affairs
Dr George Badescu is Vice President Scientific Affairs at Heidelberg Pharma and has over 15 years of experience in the biotechnology sector. He most recently served as Vice President Scientific Affairs at Abzena Plc where he led the scientific promotion and commercialization of Abzena’s Technologies and Chemistry Research and Manufacturing Services. Prior to this, he led PolyTherics’ Antibody Drug Conjugates (ADCs) program since its inception and is co-inventor on several patents in the field of bioconjugation and ADCs. Prior to this, George has worked on lead identification by viral display technologies, antibody engineering and characterisation of antibody-hapten interactions. George received his PhD from the University of Warwick.
Technical Business Development Manager
Giorgio is part of the Business Unit, with responsibility of coordinating Business Development activities He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager than moved to BD in 2014. Prior to joining BSP Pharmaceuticals, Giorgio has achieved a significant experience in Manufacturing and Operation at Bristol Mayers-Suibb where developed his professional and technical growth. Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia.
Chief Executive Officer
From 2010 to 2015, he served as an Executive Director of Business Development at PPD/BioDuro, where he was responsible from business strategy formulation to collaboration and partnership establishment. Prior to joining PPD/BioDuro, Dr. Li spent 10 years at Pfizer Global Research & Development, La Jolla Laboratories and has led research programs in a number of disease areas including oncology, metabolic diseases, anti-viral, and ophthalmology. He is an inventor of Filibuvir (PF-00868554), an HCV polymerase inhibitor currently in phase II clinical trials by Pfizer and MS-553, a PKC inhibitor currently in phase I clinical trials by Mingsight. Dr. Li obtained his bachelor degree in chemistry from Peking University and Ph.D in chemistry from University of California, San Diego. He was a founding member of the Sino-American Biomedical & Pharmaceutical Professional Association (SABPA) in 2002, served as SABPA president from 2006 to 2008 and the board chairman from 2010 to 2013.
Senior Principle Scientist
Dr. Wang is the Lead, LC-MS Technical Integration/Sr. Principal Scientist in the Bioanalytical Sciences/Translation Medicine Department at Bristol-Myers Squibb. Dr. Wang graduated from Beijing University (China) in 1987 and received his Ph.D. in analytical chemistry at Michigan State University in 1994. Following postdoctoral training at the National Institutes of Health (NIH) in Maryland USA, he joined GSK in 1996 and then Bristol-Myers Squibb in 1997. Dr. Wang has 20+ years of experience in discovery and regulated bioanalysis in pharmaceutical industry. Dr. Wang has contributed in high throughput bioanalysis and bioanalytical chromatography. In recent years, Dr. Wang has been leading a group of scientists in developing ligand binding and LC-MS/MS hybrid assays for ADC bioanalysis in an LBA and LC-MS integrated approach. Currently, Dr. Wang serves as the coordinator of Regulated Bioanalysis Interest Group at ASMS and a sub-team lead of AAPS ADC bioanalysis committee.
Chief Executive Officer
Dr. Jianmin Fang received his Ph.D. degree in biology from Dalhousie University, Canada. He completed his postdoctoral training in tumour biology in the Department of Surgery at Harvard Medical School/Children’s Hospital in Boston. Then he moved to California and worked at Cell Genesys at South San Francisco as a Scientist, Senior Scientist, and Program Head and then in Panorama Research Institute at Sunnyvale as the Director for Antibody Engineering. Since 2009，Dr. Fang has been a Professor of Molecular Medicine in Tongji University at the School of Life Science and Technology in Shanghai. He has also served as the Director of Tongji University Suzhou Institute in Suzhou. Since 2012, Dr. Fang has been the member of Scientific Committee for the national “Major Drug Innovation Projects” of China. Dr. Fang is the founder and CEO of RemeGen, Ltd. a biopharmaceutical company focusing on the development of innovative antibody drugs, including antibody-drug conjugate (ADC) drugs. He is also the founder of MabPlex International, Ltd. which provides CDMO service for biologics development and manufacturing. Dr. Fang’s research has been focused on the development of antibody drugs and other therapeutics for cancer and other diseases. He has published over 50 papers in peer-reviewed journals and has over 30 granted patents. He is the inventor for a number of biological drugs in clinical development. He is the main inventor for Conbercept, a novel biologics approved for the treatment of age-related macular degeneration (ADC) by Chinese FDA. Dr. Fang is the main inventor for RC48, the first ADC drug approved for clinical trials in China, and has been playing a leadership role in the preclinical and clinical development of RC40 project.
Kangwon National University
Kristine M. Kim is Professor of Division of Biomedical Convergence, College of Biomedical Science at Kangwon National University in Korea since 2010. Prior to her faculty position, she worked in the biopharmaceutical and biotech companies (Immunex, Amgen, and Seattle Genetics) as a scientist for the development of therapeutic antibody and antibody-drug conjugates. Her current research interests include the strategies for complementary therapeutic development to reduce both resistance and the risk of relapse, as well as concurrent identification of antibody and “novel” targets for new cancer drugs. Dr. Kim earned her Ph.D. from the University of Utah. She currently serves as department chair, council member of Korea Food and Drug Administration (KFDA), and scientific advisory board member for biotechs and many associations, including Global Bio Conference sponsored by KFDA.
Vice President - Process Development & Head of Chemistry, Manufacturing & Controls
Chief Executive Officer
Dr. Mary Chaohong Hu is currently CEO of Shanghai Miracogen Inc. developing antibody drug conjugates for cancer therapeutics. She received her BS in Biochemistry from Wuhan University and Ph.D. in Molecular Biology from the Institute of Biophysics, Chinese Academy of Sciences in Beijing, China. She completed her postdoctoral training at the University of Washington, Seattle, Washington. She has over 17 years of experience working in the biopharmaceutical/ biotech industry in the US. Before moving back to China, she was Director of Bioassay Development and Process Analytics at Seattle Genetics for development of monoclonal antibodies and antibody-drug conjugates. Prior to joining Seattle Genetics, she was Director of Molecular Biology and Clinical Immunology at GSK /ID Biomedical Corporation and was responsible for preclinical and clinical development of infectious disease vaccines.
Guangzhou Medical University
Chief Executive Officer
Dr. Han has over 20 years of drug discovery experience in the biopharmaceutical/ biotech industry in the US and China. Currently he is the CEO of NewBio Therapeutics. Inc. He received his BS degree in nuclear chemistry in 1982, MS degree in physical chemistry in 1985 both from Peking University, and Ph.D. in organic chemistry from Columbia University in 1990. He conducted postdoctoral research in antibody engineering in Professor Richard Lerner’s lab (1990-1994), and postdoctoral research in synthetic organic chemistry and medicinal chemistry in Professor Dale Boger’s Lab (1994-1996), both at The Scripps Research Institute. After working in Amgen (USA) for 12 years on small molecule drug discovery and 5 years in ShangPharma (Shanghai) as an executive director in medicinal chemistry, Dr. Han joined NewBio Therapeutics (NBT, Shanghai) in 2013 as CSO, and has led NBT’s antibody-drug conjugates (ADC) discovery efforts ever since. Dr. Han has led/worked with teams to put 5 small molecules and one ADC into clinical trials.
With in-depth knowledge of the latest industry trends, I have extensive experience in antibody drug conjugate (ADC) technology, including Bi-functional ADC constructs, novel drug linker screening, analytical testing methods, and bioconjugation process development and scale-up. My last 10 years at Abbvie/Abbott has given me great experience with two ADC drugs in humans trials, including StemCentrx ADC process development work. . Prior to Abbvie, I conjugated with the Mylotarg pioneers at Coulter Pharmaceuticals in 1999, then moved to Eos Biotechnology, were we had one of the first ADC development contracts with Seattle Genetics. Eos Biotechnology was acquired by Protein Design Labs, which eventually was acquired by Abbott/Abbvie.
Takashi Nakada is a Scientist in the Biologics & Immuno-Oncology Laboratories at Daiichi Sankyo Co, Ltd.
Head, Oncology Biologics Laboratory
Toshimitsu Uenaka is Vice President, Preclinical Development at Morphotek Inc. 1984-1988 : Faculty of Pharmaceutical Science, Tokyo University 1988-1990 : Master Course of Graduate School of Pharmaceutical Science, Faculty of Pharmaceutical Science, Tokyo University 1990-1993 : PhD Course of Graduate School of Pharmaceutical Science, Faculty of Pharmaceutical Science, Tokyo University
Chief Executive Officer & President
Dr. Tse Wen Chang is the founder and CEO of Immunwork based in Taipei, Taiwan. He was the inventor of Xolair and a cofounder of Tanox, which went public in 2000, raising a record US$ 280M, and was acquired by Genentech in 2007. His new invention of T-E technology platform is suitable for developing a new class of multifunctional drugs, including ADCs and bispecific antibodies for potential applications in oncology and beyond.
Hangzhou DAC Biotech
Dr. Xiaomai Zhou obtained his Ph.D from Tufts University School of Medicine, Boston, USA. After worked as a Research Fellow at Harvard Medical School, he joined ImmunoGen, Inc and worked on the R&D of ADC drugs for 12 years. Before he was back to China, Dr. Zhou was a Principal Scientist and Project Leader in the Biopharmaceutical Department of Boehringer Ingelheim. Dr. Zhou is now a Vice President at Hangzhou DAC Biotech.
Vice President of Development
Ying Buechler joined Ambrx recently as Vice President of Development. In this role, she is responsible for protein therapeutics process development and manufacturing. Previously, she was Executive Director of Biologics Development and Manufacturing at aTyr Pharma, where she led the team comprising upstream and downstream process development, analytical and formulation development functions for more than 7 years, including the successful execution of development and manufacturing activities for multiple clinical programs. Prior to that, she was with Ambrx from 7 years and served as director of process development and characterization. She has over 20 years of biotech industrial experience on therapeutic protein development and manufacturing. She received her Ph.D. in Chemistry from University of California, San Diego.
Chief Executive Officer
Dr. Youling Wu currently holds the CEO position of Zhejiang Teruisi Pharmaceutical Inc that is located in Huzhou, Zhejiang, China focusing on Biopharmaceutical research/development and commercial production. A commercial mAb/therapeutical protein production facility that met US/FDA, EU/EMA, ICH and cFDA multiple GMP standards with 4X5,000L capacity is being built and will be ready for operation by Nov. 2015. Past US pharmaceutical/biopharmaceutical industry experiences: broad based experiences in biopharmaceutical industry including management: director, associate director of Analytical Development, CMC-Regulatory and Global Quality Control. More than 24 years experiences in biotech division of big-pharmaceutical companies（BMS and J&J）and mid-size innovated biotech companies (Genzyme and Seattle Genetics) in multiple disciplinary functional areas: analytical development, quality control, Regulatory-CMC, CMC team leader involving variety disease areas such as oncology, cardiovascular, immunology/infectious disease and recombinant vaccines. Participated or led 6 mAb blockbuster product (one ADC product- Brentuximab) development including phase 1, 2, 3 clinical development and commercial launch. Dr. Youling Wu held various management positions: director/associate director of analytical Development/Quality Control and Regulatory Affairs-CMC and CMC team leader. She has managed multi-million dollar budget and established new function for late phase development projects (phase 3). She is proficient with regulations and participate in FDA-Biopharmaceutical Industry strategic communications. She is also the author of the CMC Strategy Forum Meeting Review “Therapeutical Protein Comparability” She is responsible for and has managed Regulatory CMC strategy and she has prepared documents for multiple nation (US, EU and Canada) regulatory submissions (IND, IMPD, CTA, BLA and NDA) including a fast track project for priority review and accelerate approval. Dr. Wu has also managed CMC activities of biopharmaceutical projects through all phases including late phase (Phase 3) projects as well as tech transfers to commercial and contract manufacture (CMO) sites.
Chief Executive Officer
Dr. Ziping Wei is co-founder and Chief Executive Officer of BlissBiopharmaceutical Co., Ltd. focusing on the development of biologics in targeted therapy and immune-oncology areas. She has had over twenty-two years of industrial experience in biotechnology and biopharmaceutical development and commercialization in US and has extensive experience in CMC development of antibody and vaccine products. She held positions in biopharmaceutical development as Executive Director at Novavax, Inc., Scientific Director at MedImmune, AstraZeneca, and Senior Scientist at Bristol-Myers Squibb and Johnson & Johnson. She is familiar with process and product development, and cGMP practices, and has supported numerous global regulatory filings for clinical and commercial products. She is a highly experienced executive who has managed cross-functional teams. She has co-authored 30+ journal publications, patents, and book chapters, and 80+ scientific abstracts, presentations, and short courses at national and international conferences. Dr. Wei is a member of Board of Director and former president (2014-2015) of Chinese Biopharmaceutical Association-USA (CBA). She received her Ph.D. in Chemistry at Rutgers, the State University of New Jersey, and B.S. in Chemistry at the University of Science and Technology of China.
Technology Consultant, Bioconjugation
Ian Schwartz joined Sartorius Stedim Biotech in December 2016 as a Process Development Consultant and is Sartorius’ bioconjugate subject matter expert. Ian has over 12 years of experience in the biotechnology industry and specializes in antibody drug conjugate (ADC) and downstream protein purification process development, technology transfer and manufacturing. Ian began his career at Biogen and has moved onto positions of increasing responsibility at ImmunoGen, MedImmune and most recently Agensy, a former affiliate of Astellas Pharmaceuticals, where he started up and led the ADC process development, tech transfer, and manufacturing support group for a number of years. With more than 13 years in the biotechnology industry, Ian leads Sartorius’ bioconjugate platform and supports process development and scale up of biological and bioconjugate processes for Sartorius’ customers.
Chief Executive Officer
Head of Sales Containment
Vice President, Head of Chemistry
Dr. Sakamuri joined Ambrx as Vice President, Head of Chemistry bringing over 18 years of drug discovery experience and leadership in antibody drug conjugates, oligonucleotides, peptides and small molecules. He is an expert in developing novel platform technologies including chemical and enzymatic bioconjugations, oligonucleotide and peptide delivery and phosphate prodrugs. Prior to joining Ambrx, he co-founded Tollnine Inc. and served as Vice President, Chemistry transitioning Tollnine into a pre-clinical development company. Prior to Tollnine, Dr. Sakamuri served as Executive Director, Head of Chemistry at Solstice Biologics for over five years. As a founding employee he built the Solstice Chemistry Team, invented best-in-class siRNA-GalNAc conjugates for rare and genetic disease programs and represented Solstice in seeking pharma collaborations and venture capital fund raising. Dr. Sakamuri also served as Director of Chemistry at Traversa Therapeutics working on siRNA delivery technology. Dr. Sakamuri worked as a Project Leader at CovX developing CovX-Body technology, invented best-in-class GLP-1R agonist antibody conjugate acquired by Pfizer and completed Phase 1 studies. Dr. Sakamuri previously held roles of increasing responsibility at Orchid Pharmaceuticals and Morphochem leading small molecule drug discovery programs producing pre-clinical compounds in Oncology and Type 2 Diabetes. He was responsible for alliance management with pharma partners and managed CRO services. Dr. Sakamuri is an author of over 35 patents and publications, carried out his Postdoctoral research at Georgetown University, Washington DC and holds a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology, India.
Cell Group Leader
Dizal Pharmaceutical Inc
Wang is the Cell Group Leader at Dizal Pharmaceutical Inc, formerly known as Asia and Emerging Markets, Innovative Medicines and Early Development, AstraZeneca (AEM iMED). In this role, she is responsible for project leader of antibody-drug conjugate (ADC) programs and translational science of multiple clinical programs. Prior to this, Dr. Wang worked as project leader of multiple drug discovery programs at Astrazeneca AEM iMED. She had over 10+ years of experience in drug discovery and translation science in pharmaceutical industry. Before joining Astrazeneca AEM iMED in 2008, she held a postdoctoral position at Lorus Therapeutics Inc in Canada. She received her Ph.D in Bio/chemical engineering at University of Waterloo in 2007.
Christina von Bulow
Senior Alliance/Project Manager